JAAD Review Flags Kaposi Sarcoma as Emerging JAK Inhibitor Signal
A JAAD systematic review published online October 17, 2026 consolidates case reports of Kaposi sarcoma emerging during Janus kinase inhibitor therapy, framing it as a safety signal.
Topic
Topic
A JAAD systematic review published online October 17, 2026 consolidates case reports of Kaposi sarcoma emerging during Janus kinase inhibitor therapy, framing it as a safety signal.
A Frontiers review links cytokine mechanisms to kidney risk in biologic psoriasis therapy, but available source text offers no in…
A new study reported by Medical Dialogues links GLP-1 receptor agonist use to higher rates of onycholysis and nail discolouration…
A man who injected a gym-bought tanning peptide has been diagnosed with melanoma — a case that revives long-standing warnings abo…
Medscape reports a new study linking GLP-1 receptor agonists to nail disorders, adding to the drug class's documented cutaneous e…
A plaintiff alleges dupilumab caused cutaneous T-cell lymphoma, a rare non-Hodgkin lymphoma that mimics eczema. The complaint tri…
A Frontiers pharmacovigilance study applies FAERS disproportionality analysis to tralokinumab adverse events in atopic dermatitis…
A new study links GLP-1 receptor agonists to onycholysis — nail-plate detachment — and a broader cluster of nail disorders, addin…
A new pharmacist-facing briefing from The Pharmacist details the risks of skin lightening treatments, positioning pharmacy teams…
A Frontiers case report and literature review document vitiligo emerging in a child on dupilumab for atopic dermatitis, adding a…